GERMANTOWN, Wis.--(BUSINESS WIRE)--Global pharmaceutical chemistry services leader, Cambridge Major Laboratories, Inc. (“CML”) announced today that it has taken on a new private equity partner, American Capital, Ltd. (Nasdaq: ACAS) (“American Capital”). American Capital brings significant resources, relationships, and capital to fuel CML’s continued growth, both organically and through acquisition.
“CML has experienced substantial growth since inception due to the Company’s continued expansion of its service offering, operations and facilities. As a result, CML is now a market leader across the entire spectrum of drug development and commercialization, providing services and products to customers with early, late-stage and commercial compounds”
“The management team at CML chose to partner with American Capital based on the depth of financial resources, and strong presence within the life sciences industry,” said Brian Scanlan, President and CEO of CML. “In addition to fueling additional growth at CML, American Capital has an impressive portfolio of companies in the pharmaceutical services arena that are fully complementary to CML’s service offering.”
The partnership with American Capital will enable CML to continue its winning strategy of growing its core pharmaceutical chemistry services business, while expanding into complementary areas within the life sciences industry. CML has demonstrated annual growth in excess of 20% over the past five years, outpacing the industry by a significant margin. Earlier this year, the Company announced a major expansion of its large volume Active Pharmaceutical Ingredient (API) manufacturing facility in Germantown, WI USA due to a significant increase in its late-stage and commercial API pipeline.
“CML has experienced substantial growth since inception due to the Company’s continued expansion of its service offering, operations and facilities. As a result, CML is now a market leader across the entire spectrum of drug development and commercialization, providing services and products to customers with early, late-stage and commercial compounds,” said Kyle Bradford, Principal, Buyouts Group at American Capital. “The Company’s market position, complex chemistry abilities, outstanding execution of its service offerings, and large state-of-the-art facilities, both in the U.S. and Europe, will allow CML to continue to meet the increased outsourcing demand from pharmaceutical and biotech companies. We look forward to working with CML’s management team to substantially grow the Company, both organically and through acquisitions.”
ABOUT CAMBRIDGE MAJOR LABORATORIES
Cambridge Major Laboratories, Inc. (CML) is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API) from early preclinical development to commercial manufacture. Operating from FDA inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence including; Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance. For more information, visit us at www.c-mlabs.com.
ABOUT AMERICAN CAPITAL
American Capital is a publicly traded private equity firm and global asset manager. American Capital, both directly and through its asset management business, originates, underwrites and manages investments in middle market private equity, leveraged finance, real estate and structured products. American Capital manages $18.6 billion of assets, including assets on its balance sheet and fee earning assets under management by affiliated managers, with $118 billion of total assets under management (including levered assets). From its eight offices in the U.S. and Europe, American Capital and its affiliate, European Capital, will consider investment opportunities from $10 million to $500 million. For further information, please refer to www.AmericanCapital.com.